Collectively, these results confirmed that glutamine metabolism in NSCLC activates the FGF17/MEK5/ERK5/NRF2 signaling pathway via GLUL, thereby lowering oxidative stress levels in the tumor microenvironment and enhancing migratory and invasive capacities of tumor cells. The gene discussed is MAPK7; the disease is neoplasm.